Chromosome

Global Prenatal Testing Market Report 2024: Historical Revenue Data for 2021-2022, Estimates for 2023, Forecasts for 2024, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Venerdì, Maggio 3, 2024
Baby, Maternity, Health, Consumer, Other Health, Insight, Noninvasive prenatal testing, Pregnancy, DSM-IV codes, Research, Genetic testing, Labcorp, Government, NIPT, Amniocentesis, ESG, Thermo Fisher Scientific, Maternal death, Chromosome, Illumina, Inc., Biomarker

The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prenatal Testing Market 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The scope of the prenatal testing market is extensive and continually evolving, reflecting the dynamic landscape of technologies and methodologies employed to assess fetal health during pregnancy.
  • This market is characterized by its global reach, with varying levels of adoption and accessibility across different regions.
  • The report covers geographic regions in detail, so companies interested in expanding their geographic reach will also find this helpful study.

May is International 5p- Syndrome (Cri du Chat) Syndrome Awareness Month

Retrieved on: 
Venerdì, Maggio 3, 2024
Education, Society, International, Syndrome, Social media, Perseverance, Happiness, Life, Genetic testing, Patient, Campaign, Chromosome, Quality of life, Drink, Organization, Disability

LAKEWOOD, Calif., May 2, 2024 /PRNewswire-PRWeb/ -- The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-) Syndrome. Over sixty (60) years ago, Dr. Jerome Lejeune discovered this genetic condition by noticing a similar characteristic in several patients that he had been observing of a high pitched "cat-like sound" vocalization. After doing genetic testing on these patients, he realized the connection is caused by a permanent deletion on the "p" arm of the 5th chromosome. The 2024 awareness campaign celebrates these unique individuals by raising awareness around the world through education and community events, such the "Faces of 5p-"campaign, our "Stripy Socks" campaign, as well as a "Virtual 5K for 5p-" event and family regional gatherings.

Key Points: 
  • Celebrating the amazing and unique individuals with 5p- Syndrome throughout the month of May by spreading awareness around the world.
  • LAKEWOOD, Calif., May 2, 2024 /PRNewswire-PRWeb/ -- The 5p- Society of North America, along with families and support organizations from over 95 countries, are bringing awareness of 5p Deletion Syndrome also known as 5p Minus (5p-) Syndrome.
  • In an ongoing effort to raise awareness, members and supporters are encouraged to participate in events throughout the month.
  • * Virtual 5k for 5p-, to raise awareness and money for programs that benefit the 5p Deletion Syndrome community.

Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded

Retrieved on: 
Lunedì, Aprile 22, 2024
Science (journal), Mortality, FDA, Pediatric Research, Protein, Chromatin, Cell, Limb–girdle muscular dystrophy, Research, American Philosophical Society, National Cancer Institute, Molecular biology, Life, Gene, Quran, Food, LGMD, SMA, RNA, DMD, Spinal muscular atrophy, Infant, Dystrophin, Nationwide, Duchenne muscular dystrophy, Ageing, National academy, Hospital, Cancer research, Literature, DNA, Therapy, Gene expression, Muscular dystrophy, Chromosome, USD, Stanford University, Cancer, Islamic studies, Muscle weakness, Disease, Vilcek Foundation, Patient, Assay, Society, Listeria monocytogenes non-coding RNA, Pharmaceutical industry

Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.

Key Points: 
  • Genetic mutations in Duchenne muscular dystrophy (DMD) patients hinder the production of dystrophin, a crucial protein for muscle health.
  • Gene therapy offers a solution by addressing this genetic anomaly, allowing the body to produce dystrophin and halt muscle degeneration.
  • Ludwig Professor of Cancer Research at Stanford University, has been awarded King Faisal Prize for Science in Biology.
  • Since 1979, King Faisal Prize in its 5 different categories has awarded 295 laureates who have made distinguished contributions to different sciences and causes.

Mission Bio's New Translocation Analysis Offers Insights into Critical Safety Assessment for Gene-Edited Cell Products

Retrieved on: 
Giovedì, Aprile 25, 2024
Biotechnology, Pharmaceutical, General Health, Health, Hospitals, Genetics, Clinical Trials, Other Health, Annual, Cancer, Bar-Ilan University, CRISPR, Hope, Safety, DSM-IV codes, Chromosomal translocation, Doctor of Philosophy, Cell, Mission, DNA, Therapy, B cell, Product management, Patient, Principal, Gene, Chromosome, Society, Genome, Immune system, Medicine, Vaccine

Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics.

Key Points: 
  • Measuring predicted translocations along with on- and off-target editing at single-cell resolution can enable developers to design more efficient and safer therapeutics.
  • “Conventional bulk methods for detecting chromosomal rearrangements are limited in scale and accuracy,” said Vanee Pho, PhD, Senior Director of Product Management, Cell and Gene Therapy at Mission Bio.
  • “Through our single-cell Tapestri Platform, our latest translocation analysis provides our customers with a comprehensive picture of gene edits and unwanted chromosomal aberrations at single-cell resolution — enabling critical safety assessment of these innovative therapies.
  • “With Mission Bio’s translocation approach, we can profile off-target activity and genome-editing efficiency more robustly and with unparalleled precision.

Integrated Biosciences Partners with Project 8p Foundation to Pioneer a New Path to Groundbreaking Treatments for Chromosomal Disorders

Retrieved on: 
Martedì, Aprile 23, 2024
Biotechnology, General Health, Health, Science, Research, Nature, Publication, Machine learning, Chromosome, Partnership, Therapy, Ageing, Synthetic biology, Biology, Cell Systems, Deletion, Gene, Pharmaceutical industry

“Chromosomal disorders have traditionally been ‘too hard’ to drug due to the large number of genes affected by deletions or duplications,” said Max Wilson, Ph.D., co-founder of Integrated Biosciences.

Key Points: 
  • “Chromosomal disorders have traditionally been ‘too hard’ to drug due to the large number of genes affected by deletions or duplications,” said Max Wilson, Ph.D., co-founder of Integrated Biosciences.
  • By supplying Integrated Biosciences with unique patient-derived cell lines, translational expertise, and valuable partnership knowhow, Project 8p Foundation demonstrates its commitment to curing chromosomal disorders with novel technologies that are accessible to all.
  • The new partnership underscores a shared commitment to transforming the lives of those affected by 8p chromosomal disorders, a central goal of the Project 8p Foundation.
  • The partnership will determine how the company’s assets can be used to treat 8p and other genetic conditions.

Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib

Retrieved on: 
Martedì, Aprile 16, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Chromosome, Fast Track, Ovarian cancer, Food, Clinical research, Gynecologic Oncology (journal), Therapy, Dana–Farber Cancer Institute, Microsoft, Patient, MPH, Medicine, FRCP, Associate, Division, Pharmaceutical industry

Volastra Therapeutics , a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).

Key Points: 
  • Volastra Therapeutics , a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
  • This trial ( NCT06084416 ) is a randomized dose optimization study of once-daily oral sovilnesib at different dose levels to establish the recommended Phase 2 dose.
  • The company is also progressing its internally developed KIF18A inhibitor, VLS-1488, in an ongoing Phase 1 clinical trial ( NCT05902988 ).
  • “Advancing our two chemically differentiated KIF18A inhibitors in parallel Phase 1 clinical trials presents the rare opportunity to efficiently gather comparative clinical data,” said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra.

Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

Retrieved on: 
Lunedì, Aprile 15, 2024
Science, Other Science, Research, Oncology, Health, Medical Devices, Health Technology, Genetics, DSM-IV codes, Cytogenetics, Agilent Technologies, Safety, Certification, Birth, Pregnancy, Edible frog, Patient, Genome, Intellectual disability, European, Chromosome, IVDR, Comparative genomic hybridization, COVID-19, Medical device

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.
  • This certification demonstrates that the assay meets the higher standards established by IVDR.
  • “The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test.
  • With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU.”
    Jenipher Dalton, chief quality and regulatory officer at Agilent, summarized the announcement’s significance.

Trilogene Seeds Releases First Triploid Cannabis Seed Line

Retrieved on: 
Giovedì, Aprile 18, 2024
Multimedia, THCA, Cannabis, Gene, Seed, GMO, Research, Risk, Chromosome, Growth, Plant, Agriculture

CHICAGO, April 18, 2024 /PRNewswire/ -- Trilogene Seeds, renowned for their cutting-edge cannabis genetics and breeding techniques, unveiled their new line of triploid THCa seeds, a significant breakthrough in cannabis cultivation.

Key Points: 
  • CHICAGO, April 18, 2024 /PRNewswire/ -- Trilogene Seeds, renowned for their cutting-edge cannabis genetics and breeding techniques, unveiled their new line of triploid THCa seeds, a significant breakthrough in cannabis cultivation.
  • The introduction of triploid genetics in cannabis, a concept previously applied to other agricultural crops like seedless watermelons, affords benefits for indoor and outdoor growers, extractors, and consumers.
  • Triploids, with an additional set of chromosomes, are essentially sterile, channeling energy towards more desirable traits rather than seed development.
  • "We take an approach that prioritizes integrity and rigorous scientific validation, pushing forward innovation within the cannabis industry," said Matthew Haddad, CEO and Founder of Trilogene Seeds.

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on: 
Martedì, Aprile 2, 2024
Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points: 
  • Dr. Roizen serves as Telomir’s special advisor on age reversal.
  • The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
  • “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
  • As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Retrieved on: 
Martedì, Aprile 9, 2024
Eurostat, Diagnosis, Civil service commission, Speech, X chromosome, Brain, Medicine, MECP2, Disease, Laxative, Seizure, Nervous system, Patient, Chromosome, Committee, Knowledge, Constipation, Regulation, EMA, IRIS, Rett syndrome, Male, Intellectual disability, Clinical trial, European, COMP, Safety, European Commission, Marketing, Parent, Syndrome, DSM-IV codes, Anatomical pathology, Pharmaceutical industry

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive